Cancer-associated thrombosis: mechanisms and risk factors
Blood clot generation in people with cancer follows a process distinct from the non-cancer population. Cancer tissue is...
Most Read
KRAS-activating mutations: an independent risk factor for VTE?
Colorectal cancer (CRC) is the third most common type of cancer in Europe , after breast and prostate cancer, and...
Venous thromboembolism in patients with solid tumors: the Italian Association of Medical Oncology (AIOM) guidelines 2019
The latest guidelines for venous thromboembolism in patients with solid tumors from the Italian Association of Medical...
Modeling predictors and outcomes in myeloproliferative neoplasms and thrombosis
Myeloproliferative neoplasms (MPNs) are characterized by clonal expansion of abnormal hematopoietic stem cells, which...
Summary ESMO Clinical Practice Guideline for the management of venous thromboembolism in cancer patients
Venous thromboembolism (VTE) is the second cause of death in people with cancer, after cancer itself. Cancer and VTE...
PROGRAM AVAILABLE: 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Program available for the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH), Bangkok,...
The CAT patient experience and the need for greater awareness of CAT
Ann Marie O’Neill is the Patient Founder and acting CEO at Thrombosis Ireland. After surviving several blood clot...
Welcome LEO Pharma
Founded in 1908, LEO Pharma is a foundation-owned company that has devoted decades of research and development to...
Awareness of venous thromboembolism risk in cancer patients: the oncologist knowledge gap
The management of cancer-associated venous thrombosis (CAT) is particularly challenging because of a high risk of major...
Flash Interviews from the 11th ICTHIC
Anna-Karin Olsson: What are the main take-home messages from “Neutrophil extracellular traps promote...